Physician profile
James T Thomas
NPI 1700845427
$35,263.46
in general payments reported to CMS, 2019-2025
41 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,686 · 2020: $1,453 · 2021: $1,814 · 2022: $1,878 · 2023: $1,702 · 2024: $1,138 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $24K · Food and Beverage: $3,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $23,583.33 |
| Food and Beverage | $3,849.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $23,603.44 | 2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $1,297.14 | 2019-2025 | Esprit, Coroflow, Gallant |
| Novartis Pharmaceuticals Corporation | $1,167.91 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $953.24 | 2019-2024 | Xarelto |
| Bard Peripheral Vascular, INC. | $892.83 | 2019-2022 | |
| Amgen INC. | $874.37 | 2019-2024 | Repatha |
| Pfizer INC. | $805.46 | 2019-2025 | |
| Shockwave Medical, INC | $803.04 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Avinger INC. | $713.47 | 2020-2023 | Pantheris |
| Merck Sharp & Dohme LLC | $517.26 | 2021-2025 | Verquvo |
| Cardiovascular Systems INC. | $458.05 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $428.18 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $348.69 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $332.77 | 2019-2025 | Ekosonic, Cds - Mct/Cem Monitoring |
| Astellas Pharma US INC | $331.98 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.30 | 2019-2024 | Jardiance |
| Asahi Intecc USA, INC. | $207.04 | 2023-2024 | Asahi Ptca Guide Wire, Peripheral Vascular |
| E.R. Squibb & Sons, L.L.C. | $198.51 | 2019-2024 | Eliquis, Camzyos |
| Nevro Corp. | $161.98 | 2023 | Senza |
| Regeneron Healthcare Solutions, INC. | $114.39 | 2019 | |
| Tactile Systems Technology INC | $111.45 | 2021-2024 | Entre Plus, Flexitouch Plus |
| Terumo Medical Corporation | $78.38 | 2020 | |
| Abiomed | $74.10 | 2022 | |
| Cardinal Health 200 LLC | $73.28 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $55.79 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $55.19 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.68 | 2022-2025 | Lifevest |
| Getinge USA Sales, LLC | $38.39 | 2020 | |
| Silk Road Medical, INC. | $38.32 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Medtronic Vascular, INC. | $31.61 | 2019 | |
| Biotronik INC. | $30.72 | 2022 | |
| Novo Nordisk INC | $28.64 | 2023-2024 | Ozempic, Rybelsus |
| Irhythm Technologies, INC. | $23.89 | 2023 | Zio Xt Patch |
| Amarin Pharma, INC. | $18.22 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $17.93 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $17.82 | 2025 | |
| Teleflex LLC | $17.53 | 2019 | |
| Bridgebio Pharma, INC. | $15.06 | 2025 | Attruby |
| Scpharmaceuticals INC. | $14.18 | 2025 | |
| Mercator Medsystems, INC. | $14.05 | 2019 | |
| Gilead Sciences, INC. | $13.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.